Heartflow, Inc. (NASDAQ:HTFL – Get Free Report) CEO John C.M. Farquhar sold 27,230 shares of the company’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $50.00, for a total value of $1,361,500.00. Following the completion of the transaction, the chief executive officer owned 360,814 shares in the company, valued at $18,040,700. This represents a 7.02% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
John C.M. Farquhar also recently made the following trade(s):
- On Tuesday, August 18th, John C.M. Farquhar sold 32,676 shares of Heartflow stock. The stock was sold at an average price of $45.00, for a total transaction of $1,470,420.00.
- On Friday, August 14th, John C.M. Farquhar sold 15,560 shares of Heartflow stock. The shares were sold at an average price of $39.06, for a total transaction of $607,773.60.
- On Monday, August 10th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The stock was sold at an average price of $28.31, for a total transaction of $638,730.22.
- On Friday, July 10th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The shares were sold at an average price of $27.75, for a total transaction of $626,095.50.
- On Wednesday, June 24th, John C.M. Farquhar sold 38,900 shares of Heartflow stock. The shares were sold at an average price of $35.00, for a total transaction of $1,361,500.00.
- On Wednesday, June 10th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The stock was sold at an average price of $28.50, for a total value of $643,017.00.
Heartflow Price Performance
HTFL traded down $0.31 during trading on Tuesday, reaching $49.89. 1,748,540 shares of the stock traded hands, compared to its average volume of 1,534,533. The stock’s 50-day simple moving average is $31.00 and its two-hundred day simple moving average is $28.47. Heartflow, Inc. has a fifty-two week low of $20.13 and a fifty-two week high of $51.19. The stock has a market cap of $4.34 billion and a price-to-earnings ratio of -27.26.
Wall Street Analyst Weigh In
HTFL has been the subject of a number of recent research reports. Robert W. Baird set a $45.00 price objective on shares of Heartflow in a report on Friday, August 14th. William Blair started coverage on Heartflow in a research note on Monday, May 4th. They set an “outperform” rating for the company. Benchmark reissued a “buy” rating on shares of Heartflow in a report on Friday, August 14th. Freedom Capital upgraded Heartflow to a “strong-buy” rating in a report on Tuesday, June 30th. Finally, Stifel Nicolaus upped their target price on Heartflow from $40.00 to $45.00 and gave the stock a “buy” rating in a research report on Friday, August 14th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $43.43.
Check Out Our Latest Analysis on HTFL
Institutional Trading of Heartflow
Several hedge funds have recently added to or reduced their stakes in HTFL. Caitong International Asset Management Co. Ltd acquired a new stake in Heartflow in the 4th quarter valued at approximately $27,000. Russell Investments Group Ltd. acquired a new position in Heartflow during the 4th quarter valued at $45,000. Essential Partners LLC bought a new stake in Heartflow in the 1st quarter valued at $57,000. Legal & General Group Plc acquired a new stake in Heartflow in the 3rd quarter worth $59,000. Finally, Strs Ohio bought a new position in shares of Heartflow during the 4th quarter worth about $99,000.
Heartflow Company Profile
HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.
HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.
Featured Stories
- Five stocks we like better than Heartflow
- Pathward’s Credit Scare Tests Its Comeback Story
- Wiring the AI Boom: Rumble’s $13.7B Pivot
- StoneX: Too Far Too Fast?
- DICK’s Sporting Goods Faces Pain Now for a Bigger Prize
Receive News & Ratings for Heartflow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heartflow and related companies with MarketBeat.com's FREE daily email newsletter.
